Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W15D | ISIN: US00182C1036 | Ticker-Symbol: BSFA
Stuttgart
12.05.26 | 20:18
67,50 Euro
0,00 % 0,00
1-Jahres-Chart
ANI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ANI PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
67,0068,5007:22
67,0068,5007:02

Aktuelle News zur ANI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised1
ANI PHARMACEUTICALS Aktie jetzt für 0€ handeln
SaANI Pharma: EPS übertrifft Schätzungen um 0,60 $ - Umsatz besser als erwartet1
FrANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program2
FrANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates1
FrANI Pharmaceuticals Non-GAAP EPS of $2.05 beats by $0.75, revenue of $237.5M beats by $29.87M1
FrANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance518Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin- Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available...
► Artikel lesen
FrANI PHARMACEUTICALS INC - 10-Q, Quarterly Report-
FrANI PHARMACEUTICALS INC - 8-K, Current Report-
24.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET1
20.04.Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?2
20.04.ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics2
20.04.ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook2
20.04.ANI Pharmaceuticals bringt Pimozid-Generikum auf den US-Markt1
20.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity355PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets...
► Artikel lesen
13.04.ANI Pharmaceuticals führt Carbamazepin-Generikum ein2
13.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules156PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200...
► Artikel lesen
08.04.ANI Pharmaceuticals Launches Generic Monoket Following FDA Approval; Shares Rise In Pre-Market-
08.04.ANI Pharmaceuticals startet Vertrieb von Isosorbidmononitrat-Generikum2
08.04.ANI Pharmaceuticals launches generic isosorbide mononitrate tablets2
08.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet432PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration...
► Artikel lesen
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1